Rhee · DNA repair 2011 · in vitro and in vivo molecular laboratory study · n=?

Factors that influence telomeric oxidative base damage and repair by DNA glycosylase OGG1.

Cited 123 times in the scientific literature.

Level 5 - mechanism / opinion, no new human data

Bench and in vivo molecular laboratory experiment without clinical data

PubMed 20951653 · doi:10.1016/j.dnarep.2010.09.008 · record verified 2026-08-30

What was done

The authors investigated the susceptibility of telomeric DNA to oxidative base damage (7,8-dihydro-8-oxoguanine, or 8-oxodG) and evaluated how telomeric sequence, structures, and proteins influence repair by 8-oxoguanine DNA glycosylase (OGG1). They compared oxidative base damage and repair efficiency between telomeric TTAGGG repeats and non-telomeric TG repeats in vivo, evaluated OGG1 incision activity across telomeric and non-telomeric double-stranded substrates, assessed whether telomere repeat binding factors TRF1 and TRF2 interfere with OGG1, and measured OGG1 excision efficiency across distinct telomeric configurations (fork-opening, 3'-overhang, and D-loop structures).

What was found

No quantitative values, effect sizes, or statistical metrics are reported in the abstract. Telomeric TTAGGG repeats were more prone to oxidative base damage and repaired less efficiently than non-telomeric TG repeats in vivo. OGG1 incision activity on double-stranded telomeric substrates was similar to non-telomeric substrates, and neither TRF1 nor TRF2 impaired OGG1 incision. However, OGG1 excision of 8-oxodG was less effective in specialized telomeric structures (fork-opening, 3'-overhang, and D-loop) depending on lesion position.

Why it matters

This study provides a mechanistic basis for telomere vulnerability under oxidative stress, demonstrating that specific structural conformations at chromosome ends hinder OGG1-mediated base excision repair.

Limits

The abstract provides no numerical data, sample sizes, or specific biological models (cell types or organisms). Findings reflect bench and in vivo mechanistic assays that cannot be directly translated to human clinical endpoints without further validation.

Cited by